image: Paul Ellison, PhD view more
Credit: Paul Ellison, PhD
Reston, Virginia—The SNMMI Mars Shot Research Fund is excited to announce that Paul Ellison, PhD, assistant professor at the Department of Medical Physics at the University of Wisconsin School of Medicine and Public Health in Madison, has been selected as the recipient of a $500,000 grant from the 2023 Mars Shot Fund. The grants recognize individuals who have made transformative impact in the field and elevated the value of nuclear medicine and molecular imaging.
The grant is one of five awarded in the inaugural year of the new SNMMI Mars Shot Research Fund, which was established to provide resources that translate visionary nuclear medicine imaging, radiopharmaceutical therapy and data science research or projects into tools or treatments that will help improve the lives of patients.
Ellison’s Mars Shot grant was awarded based on his proposal, “Modernizing radiobromine: improved radiohalogenation methodologies for translating 76/77Br theranostics.”
Theranostic radiopharmaceuticals select and stratify patients, quantifying dosimetry from non-invasive positron emission tomography (PET) imaging and delivering treatment with a chemically matched therapeutic analogue. There has been considerable success in labeling larger molecules using a suitable chelating group and appropriate diagnostic or therapeutic radiometal nuclide; however, many small-molecule biological targeting vectors are incompatible with radiometal labeling strategies due to changes in biological activity resulting from the addition of a bulky, charged metal-chelator moiety.
“To fully harness the power of cancer theranostics, there is an urgent need for theranostic pairs of radionuclides appropriate for labeling small molecules that cannot be labeled via radiometal chelation,” Ellison said. “The long-term goal and ‘Mars Shot’ of this work is to develop Br as a true theranostic pair of radionuclides that will rapidly enable development of small molecule cancer theranostics. Proof-of-concept will be demonstrated for norepinephrine transporter avid agents for neuroendocrine tumors, but the technology is also appropriate for labeling radiopharmaceuticals specific to PSMA, FAPI, CXCR4 and the host of new molecular targets that will undoubtedly emerge, accelerating the development of theranostics for other cancers in the future and benefitting a range of industrial and academic researchers.”
“Modernizing radiobromine: improved radiohalogenation methodologies for translating 76/77Br theranostics,” Paul A. Ellison, University of Wisconsin (Principal Investigator); Peter J. H. Scott, University of Michigan (Co-principal Investigator); Melanie S. Sanford, University of Michigan (Co-principal Investigator). Co-Investigators: Jonathan W. Engle, (University of Wisconsin); Allen F. Brooks (University of Michigan).
###
About the SNMMI Mars Shot Research Fund
The ‘Mars Shot for Nuclear Medicine, Molecular Imaging, and Molecularly Targeted Radiopharmaceutical Therapy’ is a forward-looking glimpse into the future of nuclear medicine. Its goal is to provide resources for the translation of visionary nuclear medicine imaging, radiopharmaceutical therapy, and data science research or projects into tools or treatments helping improve the lives of patients.
About the Society of Nuclear Medicine and Molecular Imaging
SNMMI’s members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit www.snmmi.org.